Table 2.
Mutations Identified in the Sample Set That Have Been Selected in Vivo or in Vitro by Other Investigational HIV Integrase Inhibitorsa
| |
HIV-1 subtype/CRFb |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mutation | A (N = 14) | B (N = 15) | C (N = 12) | D (N = 11) | F (N = 12) | G (N = 7) | H (N = 1) | CRF01 (N = 9) | CRF02 (N = 34) | CRF22 (N = 4) | CRF37 (N = 1) | Total (N = 120) |
| V72I | 2 (14.3) | 9 (0.6) | 7 (5.8) | 4 (36.4) | 6 (50) | 7 (100) | 1 (11.1) | 24 (70.1) | 60 (50) | |||
| M154I | 2 (2.2) | 1 (4.4) | 3 (2.5) | |||||||||
| V165I | 4 (26.7) | 1 (9.1) | 2 (16.7) | 1 (14.3) | 1 (100) | 3 (33.3) | 1 (4.2) | 13 (10.8) | ||||
| V201I | 13 (92.9) | 6 (40) | 12 (100) | 11 (100) | 12 (100) | 7 (100) | 1 (100) | 9 (100) | 34 (100) | 4 (100) | 1 (100) | 110 (91.7) |
a
The number and percentage (in parentheses) of each mutation are shown for each subtype/CRF.
b
HIV-1 subtype/CRF assignment is based on IN.